ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics (NYSE: ADCT) said enrollment is complete in its LOTIS-7 Phase 1b trial of ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab (COLUMVI) for relapsed/refractory DLBCL. 100 patients were dosed at 150 µg/kg; full data are expected in Q4 2026. Prior reported ORR was 89.8% with 77.6% CR.
How this was made
The 30-second read
Why it matters
The company’s new information is operational: enrollment is complete at the selected 150 µg/kg dose level for the ZYNLONTA + glofitamab arm, with full data targeted for Q4 2026 and plans to present and publish by end-2026.
Market read
Traders get a timeline-confirming milestone (enrollment complete) but no new efficacy/safety numbers, so the tradable catalyst is deferred to the Q4 2026 full-data window.
What to watch
Key decision points (regulatory pathway, publication, and whether results sustain prior ORR/CR with longer follow-up) are deferred to later 2026, which can dilute near-term trading impact.
Background
LOTIS-7 is a Phase 1b global study testing ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies, including glofitamab, in r/r DLBCL.
Ticker impact
ADC Therapeutics says LOTIS-7 enrollment is complete with 100 r/r DLBCL patients dosed at ZYNLONTA 150 µg/kg plus glofitamab; full data expected Q4 2026.
Likely modest positive bias; near-term upside is limited until LOTIS-7 full results are released in Q4 2026.
The release is a concrete operational milestone (enrollment complete) but does not add new efficacy/safety datapoints beyond previously reported ORR/CR, so incremental repricing should be limited.
Market effects
Supports sentiment for CD19 ADC and bispecific combination strategies in relapsed/refractory DLBCL, but without new clinical outcomes it’s not a sector reset.
No direct regional market linkage; enrollment split is US/EU but the market impact is company-specific.
Global multicenter trial progress is relevant to ADC/bispecific development pipelines, though the market will wait for confirmatory efficacy/safety results.
Counterpoint
Enrollment completion may be largely expected; without fresh efficacy/safety data, the market may treat it as routine trial progress rather than a value inflection.
Key entities
- companyADC Therapeutics SA
Commercial-stage ADC developer; subject of the press release announcing LOTIS-7 enrollment completion.
- productZYNLONTA (loncastuximab tesirine-lpyl)
CD19-directed antibody-drug conjugate used in the LOTIS-7 combination regimen.
- productglofitamab (COLUMVI)
Bispecific antibody combined with ZYNLONTA in the LOTIS-7 Phase 1b arm.
- clinical_trialLOTIS-7
Phase 1b open-label trial evaluating ZYNLONTA combinations in relapsed/refractory B-cell non-Hodgkin lymphoma.
